Maria Elena Hernandez-Aguilar

Dr. Maria Elena Hernandez-Aguilar

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in NeuroSci
Verified
Journal Article
Open access
PDF file
SLSandra Yasbeth Lara
Sandra Yasbeth Lara
ÁFÁngel de Jesús Laureani Fierro
Ángel de Jesús Laureani Fierro
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
María Rebeca Toledo-CardenasMaría Rebeca Toledo-Cardenas
María Rebeca Toledo-Cardenas
Luis I. GarcíaLuis I. García
Luis I. García
CECESAR ANTONIO PEREZ ESTUDILLO
CESAR ANTONIO PEREZ ESTUDILLO
For years, the biochemical processes that are triggered by harmful and non-harmful stimuli at the central nervous system level have been extensively studied by the scientific community through numerous techniques and animal models. For example, one of these techniques is the use of immediate expression genes, which is a useful, accessible, and reliable method for observing and quantifying cell activation. It has been shown that both the c-fos gene and its protein c-Fos have rapid activation after stimulus, with the length of time that they remain active depending on the type of stimulus and the activation time depending on the stimulus and the structure studied. Fos requires the participation of other genes (such as c-jun) for its expression (during hetero-dimer forming). c-Fos dimerizes with c-Jun protein to form factor AP-1, which promotes the transcription of various genes. The production and removal of c-Fos is part of cellular homeostasis, but its overexpression results in increased cell proliferation. Although Fos has been used as a marker of cellular activity since the 1990s, which molecular mechanism participates in the regulation of the expression of this protein is still unknown because the gene and the protein are not specific to neurons or glial cells. For these reasons, this work has the objective of gathering information about this protein and its use in neuroscience.

30 June 1999 in Hormones and Behavior
Verified
Journal Article
Closed access
Jorge ManzoJorge Manzo
Jorge Manzo
MCM.R. Cruz
M.R. Cruz
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
PPP. Pacheco
P. Pacheco
BSB.D. Sachs
B.D. Sachs

1 April 2013 in Behavioural Brain Research
Verified
Journal Article
Closed access
DVD. Vazquez-Sanroman
D. Vazquez-Sanroman
CSCarla Sanchis-Segura
Carla Sanchis-Segura
RTR. Toledo
R. Toledo
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Jorge ManzoJorge Manzo
Jorge Manzo
MMM. Miquel
M. Miquel

1 July 2020 in Medical Hypotheses
Verified
Journal Article
Closed access
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
FRFausto Rojas-Durán
Fausto Rojas-Durán

1 July 1997 in Brain Research
Verified
Journal Article
Closed access
PPPablo Pacheco
Pablo Pacheco
MCMiguel Angel Camacho
Miguel Angel Camacho
Luis I. GarcíaLuis I. García
Luis I. García
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
PCPorfirio Carrillo
Porfirio Carrillo
Jorge ManzoJorge Manzo
Jorge Manzo

10 October 2020 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
JAJosé D. Aranda-Martínez
José D. Aranda-Martínez
RARamiro Araújo
Ramiro Araújo
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
FRFausto Rojas-Durán
Fausto Rojas-Durán
Background We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine. Methodology In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days. Results This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2. Conclusion Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.